ArcherDx is a designer and manufacturer of sequencing assays purpose built to identify mutations and gene fusions from clinical sample types.
December 17, 2019
ArcherDx raises a $55,000,000 series C round from ArrowMark Partners, Boulder Ventures, Driehaus Capital Management, Longwood Fund, Perceptive Advisors, Redmile Group, Sands Capital Ventures, Soleus Capital Management and pbm capital group.
May 15, 2019
ArcherDx raises a $60,000,000 series B round.
ArcherDx raises a $35,000,000 series A round from Boulder Ventures, Longwood Fund, PBM Capital and Peierls Foundation.
ArcherDx was founded by Jason Myers.
Documentaries, videos and podcasts
June 23, 2020
Personalized cancer test developer ArcherDX is walking away from plans to take itself public and into the arms of genetic testing company Invitae.
June 8, 2020
An international pandemic notwithstanding, the cancer-focused genomic testing company ArcherDX is forging ahead with a $100 million IPO, following a busy month of pharma partnerships and FDA announcements.
May 26, 2020
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX's personalised assay will be used in AstraZeneca's recently launched Phase III MERMAID-1 trial to evaluate the effect of adjuvant treatment with Imfinzi (durvalumab) plus chemotherapy versus chemotherapy alone on disease-free survival (...
May 14, 2020
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) - read this article along with other careers information, tips and advice on BioSpace